601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)
Condition(s):Pathological Myopic Choroidal NeovascularizationLast Updated:June 10, 2021Unknown status
Hide Studies Not Open or Pending
Condition(s):Pathological Myopic Choroidal NeovascularizationLast Updated:June 10, 2021Unknown status
Condition(s):Pathologic MyopiaLast Updated:July 19, 2019Completed
Condition(s):Myopic Choroidal NeovascularisationLast Updated:March 30, 2023Completed
Condition(s):Choroidal Neovascularization Secondary to Pathologic MyopiaLast Updated:March 19, 2024Recruiting
Condition(s):Myopic Choroidal NeovascularizationLast Updated:June 18, 2023Completed
Condition(s):Myopic Choroidal NeovascularizationLast Updated:November 25, 2008Completed
Condition(s):Myopic Choroidal NeovascularizationLast Updated:January 1, 2014Unknown status
Condition(s):Myopic Choroidal Neovascular MembraneLast Updated:September 2, 2015Withdrawn
Condition(s):Choroidal Neovascularization; Myopia, DegenerativeLast Updated:November 1, 2011Completed
Condition(s):Choroidal NeovascularisationLast Updated:April 19, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.